CLINICAL EFFICACY OF COMBINATION THERAPY WITH PERINDOPRIL AND INDAPAMIDE IN PATIENTS WITH MILD AND MODERATE ARTERIAL HYPERTENSION

Aim: to study hypotensive and organo-protective efficacy of cornbination therapy with perindopril and indanarnide in patients with rnild and rnoderate arterial hypertension. Material and methods. According to the protocol in the study included 23 patients with I-II grade of arterial hypertension (ESC/ ESH 2013), of both genders. All patients took the cornbination preparation Arnra forte (GMP, Georgia), containing 4 тд of perindopril and 1.25 rrig of indaparnide. At the stage before the treatrnent and 12 weeks of therapy was rneasured an office blood pressure by Korotkov's rnethod and carried out arnbulatory blood pressure rnonitoring (ABPM) ("BR-102 plus Recorder" (SCHILLER, Switzerland)). Antirernodeling efficacy was assessed by the dynarnics of cardiac echo geornetry and ultrasound (US) of vessels pararneters. Also was evaluated the clinical tolerance and rnetabolic effects of the drug. The pararneters of central hernodynarnics and vascular stiffness were rneasured by applanation tonornetry. Results are presented as M±SD. Results of research. 12-week cornbination therapy with perindopril and indaparnide is characterized by high antihypertensive efficacy, with a decrease in rnean blood pressure to 18%, and achievernent the target level of blood pressure in 100% patients with rnild and rnoderate arterial hypertension. According to the ABPM showed a significant decrease of average daily SBP and DBP, as well as a significant decrease in the speed of rnorning SBP surge. Thus it was not iriarked episodes of hypotension at night. Reliable antirernodeling efficacy of perindopril and indaparnide is expressed in reducing LVMI, reducing of EDD and reliably reducing the thickness of IMC against the background of 12-week treatrnent. 12-week cornbination therapy with perindopril and indaparnide showed renal protection efficiency, expressing in a significant decrease in blood creatinine level and alrnost twofold reduction of MAU level. Perindopril and indaparnide in the rnode of cornbination therapy in patients with rnild and rnoderate arterial hypertension showed rnetabolic neutrality in relation to lipid and carbohydrate metabolism, clinical safety. A side effect as dry cough was observed in one patient only at the end of 12-weeks treatrnent (4.3%). Conclusion. Therefore, our research showed a high antihypertensive efficacy of cornbination therapy with perindopril and indaparnide with the available cardio-, vaso-, and nefroprotection, rnetabolic neutrality and clinical safety that recommends the preparation for the treatrnent of patients with rnild and moderate arterial hypertension.

артериальная гипертензия, суточное мо-ниторирование артериального давления, гипертрофия левого желудочка, периндоприл/индапамид, hypertension, left ventricular mass index, left ventricular hypertrophy, intimae-media thickness, microalbuminuria, perindopril, indapamide

1. Mancia G., Laurent S., Agabiti-Rosei E. et al. J. Hypertens. 2009;27:2121-2158.

2. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010;3:5-26.

3. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-1187.

4. Sever P.S., Messerli F.H. Hypertension management 2011: optimal combination therapy Eur Heart J 2011;32:2499-2506.

5. Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и аналитическая группа исследования ПИФАГОР. Анализ врачебной практики проведения антигипертензивной терапии в России (по данным исследования ПИФАГОР III). Фарматека 2009;12:98-103.

6. Мартынюк Т.В., Колос И.П., Чазова И.Е. от имени соис-следователей программы СТРАТЕГИЯ. Эффективность и безопасность фиксированной комбинации малых доз периндоприл/индапамида у пациентов с артериальной гипертонией в условиях реальной клинической практики (многоцентровое, открытое, проспективное исследование СТРАТЕГИЯ). Кардиоваск тер и проф 2007;8:21-27.

7. Чазова И.Е., Ратова Л.Г., Мартынюк Т.В. Первые итоги Российского исследования СТРАТЕГИЯ А (РоСсийская программа по оценке эффекТивности нолипРела А форТе у пациентов с артЕриальной Гипертонией высокого риска и недостаточным контролем артериального давлениЯ) - на пути оптимизации антигипертензивной терапии у больных АГ высокого риска. Системные гипертен-зии 2010;4:41-48.

8. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag 2008:4443-451.

9. Dahldf B., Gosse P., Gueret P. et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:20632070.

10. Mogensen C.E., Viberti G., Halimi S. et al. Preterax in Albuminuria Regression (PREMIER) Study Groupe. Effect of low-dose perindopril/ indapamide on albuminuria in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003;41:1063-1071.

11. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:828-840.

12. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC); J. Hypertension 2007; 25 (6): 1105-1187.

13. ADVANCE - Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med. 2005; 22: 882-888.

14. Devereux R., Pini R., Aurigeunna G., Roman M. Measurement of left ventricular mass: methodology and expertise. J Hypertens.1997;15:801-809.

15. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bdhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.

16. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.

17. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898.

18. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.

19. Li Y, Thijs L, Hansen TW, et al; International Database on Ambulatory Blood Pressure Monitiring in Relation to Cardiovascular Outcomes Investigators. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension. 2010;55:1040-1048.

20. Yusoff K, Razak TA, Yusof N, et al. Comparative efficacy of perindopril and enalapril once daily using 24-hour ambulatory blood pressure monitoring. Int J Clin Pract. 1999;53:277-280.

21. Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. Can J Cardiol. 1996;12:1191-1196.

22. Mallion JM, Asmar R, Boutelant S, et al. Twenty-four hour antihypertensive efficacy of indapamide, 1.5-mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol. 1998;32:673-678.

23. Маньковский Б.Н., Иванов Д.Д. Влияние антигипертен-зивной терапии на функцию почек у больных сахарным диабетом 2-го типа: результаты проспективного исследования "СКИФ-2". Лики Украши 2010;8:144.

24. Chaffman M, Heel RC, Brogden RN et al. Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984;3(28):189-235.

25. Ferreira R. Thiazide diuretics in hypertension. E-JASC Council Cardiology Practice 2010;35(18)/ URL:www.escardio.org

26. Трухан Д.И., Викторова И.А. Диуретики в лечении артериальной гипертонии: выбор препарата с позиции рациональной фармакотерапии и фармакоэкономической эффективности. Справ.поликлин.врача 2011;8:31-4.

27. Павлова Т.В. Роль диуретиков в лечении АГ. Справ.поли-клин.врача 2013;7:37-41.

28. Недогода С.В. Диуретики при артериальной гипертензии: ангелы и демоны. Рос.кардиол.журн. 2013;3:62-6.